Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Open accessThe DOI matches its Crossref record; 273 of the 276 references it cites were found in a registry or an index.
Abstract
We describe a recently recognized disease entity, limbic-predominant age-related TDP-43 encephalopathy (LATE). LATE neuropathological change (LATE-NC) is defined by a stereotypical TDP-43 proteinopathy in older adults, with or without coexisting hippocampal sclerosis pathology. LATE-NC is a common TDP-43 proteinopathy, associated with an amnestic dementia syndrome that mimicked Alzheimer's-type dementia in retrospective autopsy studies. LATE is distinguished from frontotemporal lobar degeneration with TDP-43 pathology based on its epidemiology (LATE generally affects older subjects), and relatively restricted neuroanatomical distribution of TDP-43 proteinopathy. In community-based autopsy cohorts, ∼25% of brains had sufficient burden of LATE-NC to be associated with discernible cognitive impairment. Many subjects with LATE-NC have comorbid brain pathologies, often including amyloid-β plaques and tauopathy. Given that the 'oldest-old' are at greatest risk for LATE-NC, and subjects of advanced age constitute a rapidly growing demographic group in many countries, LATE has an expanding but under-recognized impact on public health. For these reasons, a working group was convened to develop diagnostic criteria for LATE, aiming both to stimulate research and to promote awareness of this pathway to dementia. We report consensus-based recommendations including guidelines for diagnosis and staging of LATE-NC. For routine autopsy workup of LATE-NC, an anatomically-based preliminary staging scheme is proposed with TDP-43 immunohistochemistry on tissue from three brain areas, reflecting a hierarchical pattern of brain involvement: amygdala, hippocampus, and middle frontal gyrus. LATE-NC appears to affect the medial temporal lobe structures preferentially, but other areas also are impacted. Neuroimaging studies demonstrated that subjects with LATE-NC also had atrophy in the medial temporal lobes, frontal cortex, and other brain regions. Genetic studies have thus far indicated five genes with risk alleles for LATE-NC: GRN, TMEM106B, ABCC9, KCNMB2, and APOE. The discovery of these genetic risk variants indicate that LATE shares pathogenetic mechanisms with both frontotemporal lobar degeneration and Alzheimer's disease, but also suggests disease-specific underlying mechanisms. Large gaps remain in our understanding of LATE. For advances in prevention, diagnosis, and treatment, there is an urgent need for research focused on LATE, including in vitro and animal models. An obstacle to clinical progress is lack of diagnostic tools, such as biofluid or neuroimaging biomarkers, for ante-mortem detection of LATE. Development of a disease biomarker would augment observational studies seeking to further define the risk factors, natural history, and clinical features of LATE, as well as eventual subject recruitment for targeted therapies in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Statistical analyses on data related to LATE from the Rush University community-based autopsy cohort depicting the results of pathway analyses. Data were analysed from research volunteers (total n = 1309) in two clinical‐pathological studies of ageing from Rush University as described previously (Power et al., 2018). In this sample, the mean age of death was 89.7 years [standard deviation (SD) 6.5 years, range 65–108 years]. These analyses incorporated age, density of amyloid-β neuritic amyloid plaques (to factor in ADNC), TDP-43 proteinopathy, hippocampal sclerosis pathology, and the endpoint of Alzheimer’s-type clinical dementia. The components of the pathway analyses most strongly associated with LATE-NC are shown in red. The numbers are path coefficients with standard error in parentheses (shown in purple). These numbers help to quantify the effects of individual pathways. For instance, the data are compatible with there being two pathways from TDP-43 proteinopathy to dementia, one direct pathway (TDP-43 proteinopathy→dementia) and the other indirect pathway that includes hippocampal sclerosis pathology (TDP-43 proteinopathy→hippocampal sclerosis→dementia): in the statistical model, the TDP-43 proteinopathy is independently associated with both hippocampal sclerosis pathology and clinical dementia status. Further, the data indicate that a subset of TDP-43 proteinopathy is ‘downstream’ of ADNC-type neuritic amyloid plaque pathology. In a practical sense, this means that brains with more neuritic amyloid plaques are more likely to have TDP-43 proteinopathy, with all other known factors being the same. Aβ = amyloid-β.](https://figures.cochat.ai/paper-figures/9bc83b3adf7f42d5a250b59d9652e7a1/limbic-predominant-age-related-tdp-43-encephalopathy-late-consensus-working-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A consensus group, for example, has described hippocampal sclerosis associated with TDP-43 proteinopathy, as limbic-predominant age-related TDP-43 encephalopathy (LATE) dementia, usually found in people older than 80 years, progressing more slowly than Alzheimer's disease, detectable at post-mortem, often mimicking or comorbid with Alzheimer's disease.3”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“50–60% of Alzheimer’s-type dementia (dementia defined clinically as Alzheimer’s disease) is estimated to be attributable to these copathologies.40,42–45”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [45]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“LATE is a recently described entity which affects older people and presents with an amnestic picture resembling Alzheimer's disease 178 .”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [178]
The cited source says what the claim attributes to it.
In the citing paper
“Limbic-predominant age-related TDP43 encephalopathy (LATE), defined approximately 3 years ago, is a condition in which typical TDP43 protein inclusions are present with or without coexisting hippocampal sclerosis.29”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“The predominant neuropathological change in LATE is TDP-43 proteinopathy, which is associated with a clinical presentation of amnestic dementia that can mimic Alzheimer's dementia.”
From Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy (2020) · cites this paper as [20]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
Self-citationBlessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117 · cited 1×
“LATE-NC is mostly seen in the oldest-old, whereas in early clinical-pathological correlation studies of dementia (Roth et al., 1966; Blessed et al., 1968), the research subjects had died in their early 70s.”
BackgroundAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“This stratification will enable enrichment for subjects on the ADNC continuum (Sevigny et al., 2016) while excluding subjects likely to have high risk for LATE-NC (Botha et al., 2018).”
BackgroundMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
Self-citationStages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 1×
“seen at autopsy with every year of advanced old age (Braak et al., 2011; Nelson et al., 2011a, 2013; Brenowitz et al., 2014; Neltner et al., 2016).”
BackgroundPorta, M. (2026) · doi:10.1093/acref/9780197663639.001.0001 · Cited by 2,175
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Self-citation
Research works printed but not linked: 3
- Kuslansky G, Verghese J, Dickson D, Katz M, Busche H, Lipton RB Hippocampal sclerosis: cognitive consequences and contribution to dementia. Neurology 2004; 62: A128– 9.
- Porta M. Dictionary of Epidemiology. 6th edn. New York: Oxford University Press; 2014.
- Thom M, Sisodiya S Epilepsy. In: Love S, Perry A, Ironside JW, Budka H, editors. Greenfield’s Neuropathology. New York: CRC Press; 2015 p. 683– 739.
Cited by
Items 701–800 of 1,004
Josephs, K. A., Koga, S., Tosakulwong, N., Weigand, S. D., Pham, N. T. T., Baker, M. C., Whitwell, J. L., Rademakers, R., Petrucelli, L., & Dickson, D. W. (2023) · Free Neuropathology · doi:10.17879/freeneuropathology-2023-5192 · Cited by 13
Self-citationCholerton, B., Latimer, C. S., Crane, P. K., Corrada, M. M., Gibbons, L. E., Larson, E. B., Kawas, C. H., Keene, C. D., & Montine, T. J. (2024) · Neurology · doi:10.1212/wnl.0000000000208060 · Cited by 13
Self-citationTDP-43 seeding activity in the olfactory mucosa of patients with amyotrophic lateral sclerosis
Vizziello, M., Dellarole, I. L., Ciullini, A., Pascuzzo, R., Lombardo, A., Bellandi, F., Celauro, L., Battipaglia, C., Ciusani, E., Rizzo, A., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00833-0 · Cited by 13
Quinlan, P. S., Horváth, A., Eckerström, C., Wallin, A., & Svensson, J. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105710 · Cited by 13
Predictive value of phospho-tau/total-tau ratio in amyloid-negative Mild Cognitive Impairment
Tondelli, M., Salemme, S., Vinceti, G., Bedin, R., Trenti, T., Molinari, M. A., Chiari, A., & Zamboni, G. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136811 · Cited by 13
Torres, P., Andrés‐Benito, P., Fernàndez‐Bernal, A., Ricart, M., Ayala, V., Pamplona, R., Ferrer, I., & Portero‐Otín, M. (2020) · Brain · doi:10.1093/brain/awaa013 · Cited by 13
Inhibition of nonsense-mediated decay in TDP-43 deficient neurons reveals novel cryptic exonsPreprint
Sinha, I. R., Ye, Y., Li, Y., Sandal, P. S., Wong, P. C., Sun, S., & Ling, J. P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.28.661837 · Cited by 13
Neuroprotective effects of flavonoids
Taghizadieh, M., Modiri, N., Salmaninejad, A., Khayami, R., Taheri, F., Moghoofei, M., Khatami, A., Azhdari, S., Bayat, M., Samadi-khouzani, A., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824467-8.00016-4 · Cited by 12
Recent advances in understanding Alzheimer’s Disease: diagnosis and management strategies
Marín, A., & Budson, A. E. (2023) · Faculty Reviews · doi:10.12703/r/12-24 · Cited by 12
Age-Related Pathology in Corticobasal Degeneration
Mimuro, M., & Iwasaki, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052740 · Cited by 12
Physiological and pathological functions of TMEM106B in neurodegenerative diseases
Zhu, M., Zhang, G., Meng, L., Xiao, T., Fang, X., & Zhang, Z. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05241-z · Cited by 12
Almeida, F., Pereira, A. I., Pinto, C. M., Lopes, J., Moura, J., Sousa, J. M., Videira, G., Samões, R., & Oliveira, T. G. (2024) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8256 · Cited by 12
Yokota, O., Miki, T., Nakashima‐Yasuda, H., Ishizu, H., Haraguchi, T., Ikeda, C., Hasegawa, M., Miyashita, A., Ikeuchi, T., Nishikawa, N., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01828-6 · Cited by 12
Unveiling the veil of RNA binding protein phase separation in cancer biology and therapy
Lin, Y., Zheng, J., Mai, Z., Lin, P., Lu, Y., Li, C., & Zhao, X. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217160 · Cited by 12
Wang, X. L., Shao, X., Yu, L., Sun, J., Yin, X., Chen, Z., Xu, Y., Wang, N., Zhang, D., Qiu, W., et al. (2025) · Molecular Brain · doi:10.1186/s13041-025-01180-3 · Cited by 12
Self-citationProteomics Analysis of the TDP ‐43 Interactome in Cellular Models of ALS Pathogenesis
Cheng, F., Chapman, T. R., Venturato, J., Davidson, J. M., Polido, S. A., Rosa-Fernandes, L., Gil, R. S., Suddull, H. J., Zhang, S., Macaslam, C. Y., et al. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70079 · Cited by 12
Maurel, C., Scherer, N. M., Luu, L., Radford, R. A. W., Hogan, A. L., Merjane, J., Vidal-Itriago, A., Don, E. K., Chapman, T. R., Cull, S., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112761 · Cited by 12
TDP-43 binds to RNA G-quadruplex structure and regulates mRNA stability and translation
Zhao, J., Yang, F., Zhang, Y., Wang, H., & Kwok, C. K. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf820 · Cited by 12
Morrone, C. D., Tsang, A. A., & Yu, W. H. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00877-2 · Cited by 12
TDP-43 in Alzheimer's disease: Pathophysiology and therapeutic strategies
Zhou, X., Lin, X., He, Y., Huang, N., & Luo, Y. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107977 · Cited by 12
NMR assignments for the C-terminal domain of human TDP-43
Pantoja‐Uceda, D., Stuani, C., Laurents, D. V., McDermott, A. E., Buratti, E., & Mompeán, M. (2021) · Biomolecular NMR Assignments · doi:10.1007/s12104-020-10002-7 · Cited by 12
Yokota, O., Miki, T., Ishizu, H., Haraguchi, T., Kishimoto, Y., Takenoshita, S., Hara, N., Miyashita, A., Ikeuchi, T., Terada, S., et al. (2022) · Neuropathology · doi:10.1111/neup.12820 · Cited by 12
Brayne, C., & Wu, Y. (2022) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175221104347 · Cited by 12
Self-citationBiswas, R., Kawas, C. H., Montine, T. J., Bukhari, S. A., Jiang, L., & Corrada, M. M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221062 · Cited by 12
Self-citationComorbid neuropathology and atypical presentation of Alzheimer's disease
Piña‐Escudero, S. D., Joie, R. L., Spina, S., Hwang, J., Miller, Z., Huang, E. J., Grant, H. E., Mundada, N. S., Boxer, A. L., Gorno‐Tempini, M., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12602 · Cited by 12
Self-citationLiou, J., Li, J., Berardinelli, J., Jin, H., Santini, T., Noh, J., Farhat, N., Wu, M., Aizenstein, H. J., Mettenburg, J., et al. (2025) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaf010 · Cited by 12
Wisse, L. E. M., Ungrady, M. B., Ittyerah, R., Lim, S., Yushkevich, P. A., Wolk, D. A., Irwin, D. J., Das, S. R., & Grossman, M. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.11.012 · Cited by 12
Diverse limbic comorbidities cause limbic and temporal atrophy in lewy body disease
Sakurai, K., Kaneda, D., Morimoto, S., Uchida, Y., Inui, S., Kimura, Y., Cai, C., Kato, T., Ito, K., & Hashizume, Y. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.11.001 · Cited by 12
Ruptured mesenteric varices in hepatic cirrhosis: a rare cause of intraperitoneal hemorrhage.
Jhung, J. W., & Micolonghi, T. S. (1985) · PubMed · Cited by 12
Pini, L., Brusini, L., Griffa, A., Cruciani, F., Allali, G., Frisoni, G. B., Corbetta, M., Menegaz, G., & Boscolo Galazzo, I. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106866 · Cited by 11
APOE2 Exacerbates TDP‐43 Related Toxicity in the Absence of Alzheimer Pathology
Meneses, A. D., Koga, S., Li, Z., O'Leary, J., Li, F., Chen, K., Murakami, A., Qiao, W., Kurti, A., Heckman, M. G., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26580 · Cited by 11
Self-citationSejda, A., Wierzba‐Bobrowicz, T., Adamek, D., Gulczyński, J., Michalak, S., Grajkowska, W., & Iżycka‐Świeszewska, E. (2021) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2021.0088 · Cited by 11
A visual scale to rate amygdalar atrophy on MRI
Pizzini, F. B., Ribaldi, F., Natale, V., Scheffler, M., Rossi, V., & Frisoni, G. B. (2024) · European Radiology · doi:10.1007/s00330-024-11249-7 · Cited by 11
Dopler, M. B., Abeer, M. I., Arezoumandan, S., Cox, K., Petersen, T. L., Daniel, E. H., Cannon, C. L., Bautista, A., Blancher, K. D., Bland, A. M., et al. (2025) · FEBS Journal · doi:10.1111/febs.17413 · Cited by 11
Neuropathologic correlates of distinct plasma biomarker profiles in community-living older adults
Yu, L., Du, L., Wang, T., Barnes, L. L., Dage, J. L., Russ, K. A., Foroud, T., Bennett, D. A., Schneider, J. A., & Boyle, P. A. (2025) · Brain · doi:10.1093/brain/awaf211 · Cited by 12
Self-citationRosbergen, M. T., van der Veere, P. J., Claus, J. J., Evans, T. E., Venkatraghavan, V., Barkhof, F., van Harten, A. C., Ikram, M. A., van der Flier, W. M., Vernooij, M. W., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70413 · Cited by 11
Montoliu‐Gaya, L., Valeriano-Lorenzo, E., Ashton, N. J., López‐González, F. J., Lantero‐Rodriguez, J., Ruiz-González, A., Pastor, A. B., Frades, B., Zea‐Sevilla, M. A., Valentí, M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70562 · Cited by 11
Wang, J., Schneider, J. A., Bennett, D., Seyfried, N. T., Young‐Pearse, T. L., & Yang, H. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00910-4 · Cited by 11
Self-citationCasanova, R., Hsu, F., Barnard, R., Anderson, A., Talluri, R., Whitlow, C. T., Hughes, T. M., Griswold, M. E., Hayden, K. M., Gottesman, R. F., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12427 · Cited by 11
Santillo, A. F., Leuzy, A., Honer, M., Waldö, M. L., Tideman, P., Harper, L., Ohlsson, T. G., Moes, S., Giannini, L., Jögi, J., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06065-4 · Cited by 12
Jónsdóttir, M. K., Harrison, J., & Hannesdóttir, K. I. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12909 · Cited by 11
Carlos, A. F., Machulda, M. M., Rutledge, M. H., Nguyen, A. T., Reichard, R. R., Baker, M., Rademakers, R., Dickson, D. W., Petersen, R. C., & Josephs, K. A. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221094 · Cited by 11
Self-citationArafuka, S., Fujishiro, H., Torii, Y., Sekiguchi, H., Habuchi, C., Miwa, A., Yoshida, M., Iritani, S., Iwasaki, Y., Ikeda, M., et al. (2023) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13597 · Cited by 11
Uncovering the distinct macro-scale anatomy of dysexecutive and behavioural degenerative diseases
Corriveau‐Lecavalier, N., Barnard, L. R., Botha, H., Graff‐Radford, J., Ramanan, V. K., Lee, J., Dicks, E., Rademakers, R., Boeve, B. F., Machulda, M. M., et al. (2023) · Brain · doi:10.1093/brain/awad356 · Cited by 11
Self-citationNozal, V., Fernández-Gómez, P., García‐Rubia, A., Martínez‐González, L., Cuevas, E. P., Carro, E., Palomo, V., & Martínez, A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116626 · Cited by 11
Exploratory Mass Spectrometry of Cerebrospinal Fluid from Persons with Autopsy-Confirmed LATE-NC
Gál, J., Vary, C., Gartner, C. A., Jicha, G. A., Abner, E. L., Santos-Ortega, Y., Choucair, I., Wilcock, D. M., Nelson, R. S., & Nelson, P. T. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02239-x · Cited by 11
Self-citationNew criteria to predict LATE-NC in the clinical setting: Probable/Possible LATE and LANS
Nelson, P. T. (2024) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlae113 · Cited by 11
Self-citationsPLA2-IIA modifies progranulin deficiency phenotypes in mouse models
Yang, C., Du, H., Lee, G. B., Uematsu, M., He, W., Doré, É., Yu, W., Sanford, E. J., Smolka, M. B., Boilard, É., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00863-8 · Cited by 11
Cognitive deficit, and neuropathological correlates, in the oldest-old
Verny, M., & Duyckaerts, C. J. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2020.01.355 · Cited by 11
RNA-Based Therapies for Neurodegenerative Diseases.
Ayala, Y. M., & Nguyen, A. D. (2021) · Missouri medicine · Cited by 11
Courtier, A., Potheret, D., & Giannoni, P. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120689 · Cited by 11
Incidence and morphology of secondary TDP-43 proteinopathies: Part 1
Acewicz, A., Stępień, T., Felczak, P., Tarka, S., & Wierzba‐Bobrowicz, T. (2022) · Folia Neuropathologica · doi:10.5114/fn.2022.120314 · Cited by 11
Fisher, D. W., Tulloch, J., Yu, C., & Tsuang, D. W. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr220114 · Cited by 11
Mahady, L. J., Perez, S. E., Malek‐Ahmadi, M. H., & Mufson, E. J. (2023) · The Journal of Comparative Neurology · doi:10.1002/cne.25466 · Cited by 11
Shepherd, T. M., & Nayak, G. K. (2019) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000225 · Cited by 11
Tryptophan Probes of TDP-43 C-Terminal Domain Amyloid Formation
Shuster, S. O., & Lee, J. C. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c00767 · Cited by 11
Devenney, E. M., Nguyen, Q. A. N., Tse, N. Y., Kiernan, M. C., & Tan, R. H. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2024.101192 · Cited by 10
Yang, C., Lee, G. B., Hao, L., & Hu, F. (2025) · Communications Biology · doi:10.1038/s42003-025-07752-2 · Cited by 10
LATE-NC Stage 3: a diagnostic rubric to differentiate severe LATE-NC from FTLD-TDP
Shahidehpour, R. K., Katsumata, Y., Dickson, D. W., Ghayal, N. B., Aung, K. Z., Wu, X., Phe, P., Jicha, G. A., Neltner, A. M., Archer, J. R. C., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02876-5 · Cited by 10
Self-citationPGRN as an emerging regulator of lipid metabolism in neurodegenerative diseases
Shi, Y., Hou, W., Li, B., & Zhu, C. (2025) · Communications Biology · doi:10.1038/s42003-025-08272-9 · Cited by 10
Chatterjee, P., Ivanic, S., Southon, A. G., McCarthy, C., Patel, S. K., Christensen, M., Darby, D., Bush, A. I., Ayton, S., Werden, E., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251376694 · Cited by 10
Mosna, S., & Dormann, D. (2025) · BioEssays · doi:10.1002/bies.70084 · Cited by 10
Fox, S. H., Luca, D. G. D., Postuma, R. B., Bhidayasiri, R., Cardoso, F., Kovács, G. G., Katzenschlager, R., & Trenkwalder, C. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01206-6 · Cited by 10
Clinical–biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data
Trudel, L., Therriault, J., Macedo, A. C., Hosseini, S. A., Arias, J. F., Chan, T., Rahmouni, N., Bezgin, G., Tissot, C., Woo, M. S., et al. (2026) · Brain · doi:10.1093/brain/awag018 · Cited by 10
Trautwig, A. N., Shantaraman, A., Chung, M., Dammer, E. B., Ping, L., Duong, D. M., Watson, C. M., Petrucelli, L., Ward, M. E., Glass, J. D., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117142 · Cited by 10
Self-citationParkinson's Progression Markers Initiative brain autopsy program
Bukhari, S. A., Nudelman, K. N. H., Rumbaugh, M. C., Richeson, P., Fox, E. J., Montine, K. S., Aldecoa, I., Garrido, A., Franz, J., Stadelmann, C., et al. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.06.017 · Cited by 10
Self-citationKawakatsu, S., Kobayashi, R., Morioka, D., Hayashi, H., Utsunomiya, A., Kabasawa, T., Ohe, R., Futakuchi, M., & Otani, K. (2022) · Neuropathology · doi:10.1111/neup.12859 · Cited by 10
Baratono, S. R., & Press, D. Z. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.08.002 · Cited by 10
Casein Kinase 1δ Phosphorylates TDP-43 and Suppresses Its Function in Tau mRNA Processing
Yang, M., Qi, R., Liu, Y., Shen, X., Zhao, Y., Jin, N., Wu, R., Liu, F., & Gu, J. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220985 · Cited by 10
Oveisgharan, S., Yu, L., Agrawal, S., Nag, S., Bennett, D. A., Buchman, A. S., & Schneider, J. A. (2023) · Neurology · doi:10.1212/wnl.0000000000207726 · Cited by 10
Self-citationGodoy-Corchuelo, J. M., Ali, Z., Armas, J. M. B., Martins-Bach, A. B., García-Toledo, I., Fernández-Beltrán, L. C., López‐Carbonero, J. I., Bascuñana, P., Spring, S., Jiménez-Coca, I., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106437 · Cited by 11
Revisiting the relevance of Hirano bodies in neurodegenerative diseases
Yoshida, K., Forrest, S. L., Ichimata, S., Tanaka, H., Kon, T., Tartaglia, M. C., Tator, C. H., Lang, A. E., Nishida, N., & Kovács, G. G. (2024) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12978 · Cited by 10
A pathologic study of Perivascular pTDP-43 Lin bodies in LATE-NC
Shahidehpour, R. K., Nelson, P. T., & Bachstetter, A. D. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01826-8 · Cited by 10
Self-citationHow fiber bundle alterations differ in presumed LATE and amnestic Alzheimer's disease
Lebrun, A., Leprince, Y., Lagarde, J., Olivieri, P., Moussion, M., Noiray, C., Bottlaender, M., & Sarazin, M. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14156 · Cited by 10
Targeting the TDP-43 low complexity domain blocks spreading of pathology in a mouse model of ALS/FTD
Chevalier, E., Audrain, M., Ratnam, M., Ollier, R., Fuchs, A., Piorkowska, K., Pfeifer, A., Kosco‐Vilbois, M. H., Seredenina, T. S., & Afroz, T. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01867-z · Cited by 10
Medial temporal atrophy predicts the limbic comorbidities in lewy body disease
Sakurai, K., Kaneda, D., Morimoto, S., Uchida, Y., Inui, S., Shang, C., Kimura, Y., Cai, C., Kato, T., Ito, K., et al. (2024) · Neuroradiology · doi:10.1007/s00234-024-03502-z · Cited by 10
Hippocampal atrophy over two years in relation to tau, amyloid-β and memory in older adults
Aumont, É., Bédard, M., Bussy, A., Arias, J. F., Tissot, C., Hall, B. J., Therriault, J., Rahmouni, N., Stevenson, J., Servaes, S., et al. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.11.007 · Cited by 10
Wang, M., Chen, K., Huang, Y., Chen, S., Wang, R., Zhang, Y., Hu, H.-Y., Ma, L.-Z., Liu, W., Wang, J., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03345-z · Cited by 11
Ibarra, R., Radanovic, M., Pais, M. V., Talib, L. L., & Forlenza, O. V. (2020) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988720944237 · Cited by 10
Factors associated with slow progression of cognitive impairment following first dementia diagnosis
Perera, G., Mueller, C., & Stewart, R. J. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5420 · Cited by 10
Estimation of suspended sediment concentration in Guamá River in the Amazon region
de Oliveira, P. A., Blanco, C. J. C., Mesquita, A. L. A., Lopes, D. F., & Filho, M. D. (2021) · Environmental Monitoring and Assessment · doi:10.1007/s10661-021-08901-w · Cited by 10
Nelson, R. S., Dammer, E. B., Santiago, J. V., Seyfried, N. T., & Rangaraju, S. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.902146 · Cited by 10
Neuropathologic correlates of cerebral microbleeds in community-based older adults
Nikseresht, G., Evia, A. M., Nag, S., Leurgans, S. E., Capuano, A. W., Agam, G., Barnes, L. L., Bennett, D. A., Schneider, J. A., & Arfanakis, K. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.05.005 · Cited by 10
Self-citationCukier, H. N., Duarte, C. L., Laverde-Paz, M. J., Simon, S. A., Booven, D. J. V., Miyares, A. T., Whitehead, P. L., Hamilton‐Nelson, K. L., Adams, L. D., Carney, R. M., et al. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.07.007 · Cited by 10
Machine Learning for Alzheimer’s Disease and Related Dementias
Modat, M., Cash, D. M., Canas, L. S., Bocchetta, M., & Ourselin, S. (2023) · Neuromethods · doi:10.1007/978-1-0716-3195-9_25 · Cited by 10
Chang, H., & Wang, I. (2024) · Scientific Reports · doi:10.1038/s41598-024-55229-9 · Cited by 10
Quadri, Z., Johnson, N. J., Zamudio, F., Miller, A., Peters, M. M., Smeltzer, S., Hunt, J. B., Housley, S. B., Brown, B., Kraner, S. D., et al. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.103418 · Cited by 10
Association of Hemoglobin A1C With TDP-43 Pathology in Community-Based Elders
Oveisgharan, S., Capuano, A. W., Nag, S., Agrawal, S., Barnes, L. L., Bennett, D. A., Arvanitakis, Z., & Schneider, J. A. (2021) · Neurology · doi:10.1212/wnl.0000000000012025 · Cited by 10
Self-citationDarricau, M., Canron, M., Bosc, M., Arotçarena, M.-L., Quang, M. L., Dehay, B., Bézard, E., & Planche, V. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.07.009 · Cited by 10
Griffa, A., Legdeur, N., Badissi, M., van den Heuvel, M. P., Stam, C. J., Visser, P. J., & Hillebrand, A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.746373 · Cited by 10
Limbic-predominant age-related TDP-43 encephalopathy (LATE)
Larner, A. J., & Griffiths, T. D. (2019) · Brain · doi:10.1093/brain/awz184 · Cited by 10
Molecular Visualization of Neuronal TDP43 Pathology In SituPreprint
Erwin, A. L., Fernandez, M. G., Chang, M. L., Attili, D., Bekier, M., Pinarbasi, E. S., Russ, J. E., Sutanto, R., Thomas, D., Shen, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.19.608477 · Cited by 10
Tazwar, M., Evia, A. M., Ridwan, A. R., Leurgans, S. E., Bennett, D. A., Schneider, J. A., & Arfanakis, K. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.04.002 · Cited by 9
Self-citationCholinesterase inhibitor use in amyloid PET-negative mild cognitive impairment and cognitive changes
Pyun, J., Park, Y. H., Kang, M. J., & Kim, S. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01580-y · Cited by 9
Lu, S., Zhang, S., Oung, S., Diedrich, J. K., Han, P., Arnold-García, O., Ohkubo, T., Arogundade, O. A., Vazquez‐Sanchez, S., Zhang, K., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01789-5 · Cited by 9
Beyond Alzheimer’s disease—translating biomarker insights across CNS diseases
Brady, L. S., Mahinrad, S., Edelmayer, R. M., Potter, W. Z., Hutten, S. J., Anticevic, A., Taylor‐Burds, C., Winston, C. N., Coetzee, T., Paulsen, J. S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adr2511 · Cited by 9
Self-citationGodrich, D., Pasteris, J., Martin, E. R., Kunkle, B. W., Naj, A. C., Hamilton, K., Wang, H., Lee, W., Dumitrescu, L. C., Hohman, T. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70760 · Cited by 9
Self-citationReal‐world experience with lecanemab therapy for Alzheimer's disease in the Intermountain West
Curd, B. C., Zubrick, C., Brown, C. J. C., Sorweid, M. K., Dehoney, S. B., Anzai, Y., Minoshima, S., Parks, A. L., & Frost, N. A. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70251 · Cited by 9
Maintaining and regaining episodic memory in Alzheimer disease: a circuit-based perspective
Düzel, E., & Kreutz, M. R. (2026) · Nature Reviews Neurology · doi:10.1038/s41582-026-01189-9 · Cited by 9
Siebner, A. S., & Uversky, V. N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083669 · Cited by 9
Metadata
- Authors
- Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I., Attems, J., Brayne, C., Coyle-Gilchrist, I. T. S., Chui, H. C., Fardo, D. W., Flanagan, M. E., Halliday, G., Hokkanen, S. R. K., Hunter, S., Jicha, G. A., Katsumata, Y., Kawas, C. H., Keene, C. D., Kovacs, G. G., Kukull, W. A., Levey, A. I., Makkinejad, N., Montine, T. J., Murayama, S., Murray, M. E., Nag, S., Rissman, R. A., Seeley, W. W., Sperling, R. A., White III, C. L., Yu, L., & Schneider, J. A.
- Affiliations
- University of Kentucky (US)
- Mayo Clinic in Florida (US)
- University of Pennsylvania (US)
- Mayo Clinic (US)
- Rush University Medical Center (US)
- Uppsala University (SE)
- Newcastle University (GB)
- University of Cambridge (GB)
- University of Southern California (US)
- University of Minnesota (US)
- The University of Sydney (AU)
- University of California, Irvine (US)
- University of Washington (US)
- Institute of Neurology Medical University of Vienna, Vienna, Austria
- Emory University (US)
- Illinois Institute of Technology (US)
- Stanford University (US)
- Tokyo Metropolitan Institute of Gerontology (JP)
- University of California San Diego (US)
- University of California, San Francisco (US)
- Harvard University (US)
- University of Texas Southwestern Medical Center, Dallas, TX, USA
- Corresponding author
- Nelson, Peter T
- ORCID
- Nelson, Peter T
- Dickson, Dennis W
- Trojanowski, John Q
- Jack, Clifford R
- Boyle, Patricia A
- Arfanakis, Konstantinos
- Rademakers, Rosa
- Alafuzoff, Irina
- Attems, Johannes
- Brayne, Carol
- Coyle-Gilchrist, Ian T S
- Chui, Helena C
- Fardo, David W
- Flanagan, Margaret E
- Halliday, Glenda
- Hokkanen, Suvi R K
- Hunter, Sally
- Jicha, Gregory A
- Katsumata, Yuriko
- Kawas, Claudia H
- Keene, C Dirk
- Kukull, Walter A
- Levey, Allan I
- Makkinejad, Nazanin
- Montine, Thomas J
- Murayama, Shigeo
- Murray, Melissa E
- Nag, Sukriti
- Rissman, Robert A
- Seeley, William W
- Sperling, Reisa A
- Yu, Lei
- Schneider, Julie A
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-04-30
- Volume
- 142
- Issue
- 6
- Pages
- 1503-1527
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6536849
- OpenAlex
- W2943828894
- Cited by
- 1,547
- References
- 276
- Citations by year
- 2026: 206 · 2025: 240 · 2024: 211 · 2023: 214 · 2022: 213 · 2021: 193 · 2020: 198 · 2019: 66
- FWCI
- 113.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UKnowledge (University of Kentucky) (submittedVersion, cc-by-nc)
- Apollo (University of Cambridge) (submittedVersion, cc-by-nc)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Apollo
- Funders
- NIA
- NACC
- NIH (U01 AG016976)
- National Health and Medical Research Council
- NHMRC (1132524, 1095127, 1037746)
- Senior Principal Research Fellowship (1079679)
- National Institutes of Health (P01 AG003949, R01 AG037491, P50 AG016574, R01 AG054449, P30 AG028303, P30 AG012300, P30 AG049638, P30 AG010124, P30 AG010161, P50 AG047366, P50 AG025688, P50 AG005131, R37 AG011378, R01 AG041851, R01 AG042210, R01 AG017917, R01 AG034374, UF1 AG053983, UF1 AG057707)
- NIHR (534906, NF-SI-0616–10090)
- National Institute for Health Research
- NHS
- Department of Health and Social Care
- Addenbrooke’s Charitable Trust
- Paul G. Allen Family Foundation and Alzheimer’s Research
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- limbic-predominant age-related TDP-43 encephalopathy, TDP-43 proteinopathy, hippocampal sclerosis, diagnostic criteria, neuropathological staging, amygdala, medial temporal lobe atrophy, genetic risk variants, gene regulatory networks, TMEM106B, ABCC9, apolipoprotein E, Alzheimer's disease, frontotemporal lobar degeneration
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Brain Diseases, Female, Humans, Male, Middle Aged, Retrospective Studies, Frontotemporal Lobar Degeneration, TDP-43 Proteinopathies, Frontotemporal Dementia, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.